Loading...
•
Mar 31, 2020
Insulet Q1 2020 Earnings Report
Insulet experienced revenue increase and total Omnipod revenue growth in the first quarter of 2020.
Key Takeaways
Insulet Corporation reported a strong first quarter in 2020, with revenue reaching $198.0 million, a 24.1% increase year-over-year. Total Omnipod revenue grew by 32.7% to $189.7 million. The company's gross margin was 64.1%, and adjusted EBITDA was $24.3 million, representing 12.3% of revenue. However, the company experienced a net loss of $2.1 million, or $(0.03) per diluted share.
Revenue increased by 24.1% year-over-year to $198.0 million, exceeding guidance.
Total Omnipod revenue grew by 32.7% to $189.7 million.
U.S. Omnipod revenue increased by 35.4% to $116.6 million.
Gross margin was 64.1%, impacted by COVID-19 related costs.
Insulet
Insulet
Insulet Revenue by Segment
Revenue by Segment
U.S. Omnipod Revenue
CapyFin.comInternational Omnipod Revenue
CapyFin.comDrug Delivery Revenue
CapyFin.com Forward Guidance
Insulet expects strong revenue growth to continue in the second quarter but anticipates the most significant impact in the second half of 2020, due to the COVID-19 pandemic and recessionary headwinds.
Positive Outlook
- Recurring revenue model provides a benefit.
- Strong revenue growth is expected to continue in Q2.
- Company assumes gradual recovery starting in Q3.
- Total Omnipod revenue is expected to grow.
- U.S. Omnipod revenue is expected to increase.
Challenges Ahead
- Progression of COVID-19 is difficult to predict.
- Significant impact on new global Omnipod starts in Q2.
- Pandemic and recessionary headwinds expected to persist.
- Revenue growth will be most impacted in the second half of 2020.
- Drug Delivery revenue is expected to decline.
Revenue & Expenses
Visualization of income flow from segment revenue to net income